Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM6B | O15054 | 1/20 | 0.58 |
| ▸ | KDM4A | O75164 | 1/20 | 0.58 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.58 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.58 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | XBP1 | P17861 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | ATAD2 | Q6PL18 | 2/20 | 0.37 |
| ▸ | XDH | P47989 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20060568 | 0.79 | MAPK1 (0.61) | KDM6BKDM4AKDM4DHIF1ANKDM2A | |
| SCHEMBL2713726 | 0.78 | KDM6B (0.56) | KDM6BKDM4AKDM4DHIF1ANKDM2A | |
| SCHEMBL19725083 | 0.78 | KDM6B (0.56) | KDM6BKDM4AKDM4DHIF1ANKDM2A | |
| SCHEMBL2072718 | 0.78 | KDM6B (0.56) | KDM6BKDM4AKDM4DHIF1ANKDM2A | |
| SCHEMBL13525026 | 0.78 | KDM6B (0.61) | KDM6BKDM4AKDM4DHIF1ANKDM2A | |
| SCHEMBL16466339 | 0.78 | KDM6B (0.56) | KDM6BKDM4AKDM4DHIF1ANKDM2A | |
| SCHEMBL26063190 | 0.77 | ALDH1A1 (0.45) | KDM6BKDM4AKDM4DHIF1ANKDM2A | |
| SCHEMBL11900387 | 0.75 | LMNA (0.59) | KDM6BKDM4AKDM4DHIF1ANKDM2A | |
| SCHEMBL18689737 | 0.75 | KDM6B (0.53) | KDM6BKDM4AKDM4DHIF1ANKDM2A | |
| SCHEMBL10653223 | 0.73 | PLA2G7 (0.52) | KDM6BKDM4AKDM4DHIF1ANKDM2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023091726-A1 | INHIBITORS OF CYCLIN‑DEPENDENT KINASE 12 (CDK12) | SYROS PHARMACEUTICALS, INC. (US) | 2023-05-25 | — | — | WO | disclosed |
| US-9096624-B2 | Amino pyrimidine anticancer compounds | OSI Pharmaceuticals, LLC (US) | 2015-08-04 | — | — | US | disclosed |
| US-20130231306-A1 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | OSI Pharmaceuticals, LLC (US) | 2013-09-05 | — | — | US | disclosed |
| EP-2007751-B1 | AZABICYCLO [3. 1. O] HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LTD (GB) | 2013-08-21 | — | — | EP | disclosed |
| EP-2007751-B1 | AZABICYCLO [3. 1. O] HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LTD (GB) | 2013-08-21 | — | — | EP | disclosed |
| US-8399433-B2 | Amino pyrimidine anticancer compounds | OSI Pharmaceuticals, LLC (US) | 2013-03-19 | — | — | US | disclosed |
| US-8222266-B2 | Azabicyclo [3.1.0] hexyl derivatives as modulators of dopamine D3 receptors | GLAXO GROUP LIMITED (GB) | 2012-07-17 | — | — | US | disclosed |
| US-8222266-B2 | Azabicyclo [3.1.0] hexyl derivatives as modulators of dopamine D3 receptors | GLAXO GROUP LIMITED (GB) | 2012-07-17 | — | — | US | disclosed |
| US-8222266-B2 | Azabicyclo [3.1.0] hexyl derivatives as modulators of dopamine D3 receptors | GLAXO GROUP LIMITED (GB) | 2012-07-17 | — | — | US | disclosed |
| US-20110136764-A1 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | OSI PHARMACEUTICALS, INC. (US) | 2011-06-09 | — | — | US | disclosed |
| EP-0013071-B1 | PYRIMIDINONE DERIVATIVES, PROCESSES FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1983-11-16 | — | — | EP | disclosed |
| US-4385058-A | HISTAMINE H2-ANTAGONISTS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1983-05-24 | — | — | US | disclosed |
| EP-0015138-B1 | PYRIMIDONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1983-03-16 | — | — | EP | disclosed |
| EP-0049173-A2 | Pyrimidone derivatives, processes for their preparation and pharmaceutical derivatives containing them | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1982-04-07 | — | — | EP | disclosed |
| EP-0003677-B1 | PYRIMIDONES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1981-11-11 | — | — | EP | disclosed |
| US-4234588-A | ANTIHISTAMINES | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1980-11-18 | — | — | US | disclosed |
| EP-0015138-A1 | Pyrimidone derivatives, processes for their preparation and pharmaceutical compositions containing them | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1980-09-03 | — | — | EP | disclosed |
| EP-0013071-A1 | Pyrimidinone derivatives, processes for preparing them and pharmaceutical compositions containing them | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1980-07-09 | — | — | EP | disclosed |
| WO-1980000966-A1 | NEW HISTAMINE H2-ANTAGONISTS | SMITH KLINE FRENCH LAB (GB) | 1980-05-15 | — | — | WO | disclosed |
| EP-0003677-A2 | Pyrimidones, processes for their preparation and pharmaceutical compositions containing them | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1979-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231306-A1 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | DPYD, PTK2, TYMS | KDM6B 2179/4885KDM4A 3053/4885KDM4D 2787/4885 |
| US-20110136764-A1 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | DPYD, PTK2, TYMS | KDM6B 2179/4885KDM4A 3053/4885KDM4D 2787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.